|
WO2020251923A1
|
|
Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
|
|
US2020148791A1
|
|
Method of Generating Anti-Linaclotide Antibodies and Uses Thereof
|
|
WO2019055859A1
|
|
Treatment of metabolic syndrome with an sgc stimulator
|
|
CN111050755A
|
|
Effect of a gastroretentive bile acid sequestrant formulation
|
|
WO2019161534A1
|
|
Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
|
|
MX2019007574A
|
|
Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide.
|
|
TW201822765A
|
|
TREATMENT OF CNS DISEASES WITH sGC STIMULATORS
|
|
BR112019004468A2
|
|
sgc stimulants
|
|
CN109563087A
|
|
The solid form of sGC stimulant
|
|
BR112019000290A2
|
|
scg stimulators phosphorus prodrugs
|
|
CN108697678A
|
|
SGC stimulants are in nonalcoholic fatty liver disease(NASH)Application in treatment
|
|
CA3006764A1
|
|
Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
|
|
EP3383372A1
|
|
Solid dispersions comprising a sgc stimulator
|
|
WO2017070293A1
|
|
Phosphodiesterase 9 inhibitor and levodopa therapy
|
|
WO2016197042A1
|
|
Modified or targeted release formulations of linaclotide
|
|
BR112017023539A2
|
|
colon cleansing and gastrointestinal disorder compositions
|
|
WO2016144860A1
|
|
Faah inhibitors for the treatment or prevention of nausea
|
|
WO2016126625A1
|
|
Methods of treating upper gastrointestinal disorders in ppi refractory gerd
|
|
MX2017003518A
|
|
Sgc stimulators.
|
|
EP3194382A1
|
|
Pyrazole derivatives as sgc stimulators
|
